Related Experiment Video
Updated: Jun 3, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Suppression of lung adenocarcinoma progression by Nkx2-1
Monte M Winslow1, Talya L Dayton, Roel G W Verhaak
1David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Abstract:
Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
Insights
This study reveals that the transcription factor Nkx2-1 suppresses malignant progression in lung adenocarcinoma. Its downregulation is linked to increased metastasis and poor differentiation, highlighting its dual role in tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung adenocarcinoma, a common cancer, has poor outcomes, yet its progression mechanisms are unclear.
- Activating KRAS mutations and p53 pathway inactivation are common in lung adenocarcinoma.
Purpose of the Study:
- To model human lung adenocarcinoma in mice to investigate tumor progression and metastasis.
- To identify genetic alterations and gene expression changes associated with metastatic potential.
Main Methods:
- Conditional alleles in mice (Kras(LSL-G12D/+);p53(flox/flox)) to model lung adenocarcinoma.
- Lentiviral-mediated somatic gene activation/deletion to initiate tumors.
- Analysis of lentiviral integration sites to distinguish metastatic from non-metastatic tumors.
- Gain- and loss-of-function experiments to assess Nkx2-1 function.
Main Results:
- Nkx2-1 negativity correlates with high-grade, poorly differentiated tumors and increased metastatic potential.
- Nkx2-1 represses Hmga2, a chromatin regulator, thereby constraining tumor progression.
- Downregulation of Nkx2-1 is linked to loss of differentiation and enhanced metastatic ability.
Conclusions:
- Nkx2-1 acts as a tumor suppressor in lung adenocarcinoma by maintaining differentiation and limiting metastasis.
- Nkx2-1 exhibits dual oncogenic and suppressive functions, acting as a lineage factor.
- Understanding Nkx2-1's role is crucial for developing targeted therapies for metastatic lung cancer.